D-0012-2021 Class II Terminated
FDA drug recall D-0012-2021 was initiated by Teva Pharmaceuticals USA on Aug 24, 2020 and is designated Class II. Reason for recall: CGMP deviations; there is a possibility that some bottles in these lots may have the active ingredient above and/or below specification limits. The recall status is terminated (terminated Dec 16, 2021). Affected quantity: 103,940 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Sep 16, 2020
- Initiation Date
- Aug 24, 2020
- Termination Date
- Dec 16, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 103,940 bottles
Product description
Cephalexin for Oral Suspension, USP 125 mg per 5 mL, For Reconstitution, For Oral Use Only, Rx Only, a) 100 mL bottle when mixed, NDC 0093-4175-73, b) 200 mL bottle when mixed, NDC 0093-4175-74, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454.
Reason for recall
CGMP deviations; there is a possibility that some bottles in these lots may have the active ingredient above and/or below specification limits.
Distribution pattern
Nationwide in the U.S. and Puerto Rico.
Code information
Lot #s: a) 30309820A, Exp. 08/2020; 30310000B, 30310001B, Exp. 10/2020; 30310096A Exp. 01/2021; 30310228A, Exp. 03/2021; 30310313A, Exp. 06/2021; b) 30309861A, Exp. 08/2020; 30310335A, Exp. 06/2021.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0012-2021
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026